Results 201 to 210 of about 45,652,519 (319)

COVER BELAKANG

Jentera: Jurnal Kajian Sastra, 2021
Jentera: jurnal Kajian Sastra Volume 10, No 2, Desember 2021
doaj   +2 more sources

Front Matter Volume 10.2

Scottish Studies, 1966
[Editor]
doaj  

PLC #10

, 2019
Péter
openalex   +1 more source

coronavirus-tweet-id-2020-01-29-10.txt

, 2020
Emily Chen, Kristina Lerman, Emilio Ferrara   +2 more
openalex   +1 more source

Effect of alkyl chain length on the corrosion inhibition performance of 2-thioxo-2,3-dihydroquinazolin-4(1H)-one derivatives for carbon steel in HCl solution. [PDF]

Sci Rep
El-Maksoud SAA, Fathalla W, Saleh MS, El-Dossoki FI.   +3 more
europepmc   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

Scottish Studies, Volume 10 (1966): Full Volume

Scottish Studies, 1966
[Editor]
doaj  

Cb502 Sma-2(E502)Iii | 2011-10-13T15:53:34+01:00

, 2017
Avelino Javer, Michael Currie, Jim Hokanson, Chee Wai Lee, Kezhi Li, Eviatar Yemini, Laura J Grundy, Chris Li, Quee-Lim Ch'ng, William R Schafer, Rex Kerr, André EX Brown   +11 more
openalex   +1 more source

Functional Evaluation of Computationally Designed IL-10 in IL-10 KO Mice. [PDF]

Biomolecules
Stokes J, Hyder I, Shen Z, Ramdhan P, Bayer A, Wasserfall C, Li C, Song S.   +7 more
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source